ACHN @ Canaccord (4/1/10)
1. I'm pretty confident that either the president misspoke or I'm just reading too much into it, but at the 9:15 mark of the presentation, the president states in his introductory remarks about ACH-1625 that ACHN has a "hold up in some clinical development here" among a few other initial remarks that are otherwise clearly positive. The rest of the remarks about 1625 are also very clearly positive and the story appears to be much the same as it has been all along (high safety margins, etc.). So, I'm not sure I understand the aforementioned statement as it was clearly out of context from the rest of the discussion regarding 1625. It was probably just a misstatement or I'm reading into it too much.
2. The two ongoing cohorts of the 1625 Phase 1b trial are now almost fully enrolled and data is expected shortly after EASL.
3. According to the president, at the 5 day mark, 1625 produced the "single deepest viral load reduction that anyone has been able to produce." (13:50 mark of presentation)
4. Phase 2 for 1625 expected to begin in September.
5. Partnering chatter still the same for 1625. ACHN still feels it's right about at its first term sheet. The president indicated around the 28:30 mark that a collaboration agreement for 1625 is "likely this year."
6. ACHN has received its first term sheet for ACH-702.
